Entrada Therapeutics, Inc. Fair Value Disclosure
Fair Value Measurements at December 31, 2025 | |||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
Cash equivalents:(1) | |||||||||||||||||||||||
| Money market funds | $ | 89,894 | $ | — | $ | — | $ | 89,894 | |||||||||||||||
| Marketable securities: | |||||||||||||||||||||||
| U.S. government agency securities and treasuries | — | 188,570 | — | 188,570 | |||||||||||||||||||
| Corporate debt securities | — | 16,734 | — | 16,734 | |||||||||||||||||||
| Total | $ | 89,894 | $ | 205,304 | $ | — | $ | 295,198 | |||||||||||||||
Fair Value Measurements at December 31, 2024 | |||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
Cash equivalents: (1) | |||||||||||||||||||||||
| Money market funds | $ | 100,711 | $ | — | $ | — | $ | 100,711 | |||||||||||||||
| Marketable securities: | |||||||||||||||||||||||
| U.S. government agency securities and treasuries | $ | — | $ | 253,628 | $ | — | $ | 253,628 | |||||||||||||||
Corporate debt securities | — | 65,159 | — | 65,159 | |||||||||||||||||||
| Total | $ | 100,711 | $ | 318,787 | $ | — | $ | 419,498 | |||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Mar 13, 2024 | |
| 2022 | Mar 6, 2023 | |
| 2021 | Mar 15, 2022 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.